Tag: Atai Life Sciences - Page 2 - Psychedelic Alpha

Read more about the article atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)

atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)

Post published:April 13, 2023
Post category:Press Release

Read more about the article atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights

atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights

Post published:March 24, 2023
Post category:Press Release

Read more about the article atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates

atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates

Post published:March 6, 2023
Post category:Press Release

Read more about the article atai Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference

atai Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference

Post published:March 1, 2023
Post category:Press Release

Read more about the article atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917

atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917

Post published:January 12, 2023
Post category:Press Release

Read more about the article atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression

atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression

Post published:January 6, 2023
Post category:Press Release

Read more about the article atai’s PCN-101 Candidate Fails to Meet Primary Endpoint in Heavily-Anticipated Phase 2a Trial

atai’s PCN-101 Candidate Fails to Meet Primary Endpoint in Heavily-Anticipated Phase 2a Trial

Post published:January 6, 2023
Post category:Analysis

Read more about the article The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital

The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital

Post published:December 16, 2022
Post category:Press Release

Read more about the article atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer

atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer

Post published:November 29, 2022
Post category:Press Release

Read more about the article Racing Beyond Racemic: A Look at Ketamine Drug Development Ahead of atai’s PCN-101 Phase 2a Readout

Racing Beyond Racemic: A Look at Ketamine Drug Development Ahead of atai’s PCN-101 Phase 2a Readout

Post published:November 17, 2022
Post category:Analysis

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.